Lund, Sweden, 16 April 2019 – Sven Kili, an Executive Director and the Chief Medical Officer of Xintela, extends his commitment by taking on the Chief Operating Officer (COO) role. Sven Kili is a surgeon and specialist in orthopedics and, through leading positions in pharmaceutical companies including Genzyme, Sanofi, and GSK, has many years’ experience in the successful development and commercialization of cell and gene therapy products.
“We are very fortunate that Sven Kili now has the opportunity to increase his engagement with Xintela to 50% and take on the additional role of Chief Operating Officer. We are in a very exciting, active phase, preparing for both GMP production of our stem cell product and the start of clinical studies, and Sven’s deep experience in these areas will be of tremendous importance. In addition, with his great international network in cell and gene therapy, he will be key to Xintela’s financing and internationalization activities,” says Xintela’s CEO Evy Lundgren-Åkerlund.
“I look forward to spending more time with the Xintela team and to take on more of the challenges in the company’s development. Xintela has great ambition and potential with this technology and we have a very exciting journey ahead of us,” says Sven Kili.
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evy [at] xintela.se
223 81 Lund